Journal of diabetes and its complications, 2023 BACKGROUND AND AIM Sodium-glucose co-transporter 2 inhibitors (SGLT2i) has been verified to improve Non-alcoholic fatty liver disease (NAFLD) in previous clinical practice.
Zi-Xuan Jin +4 more
semanticscholar +1 more source
Euglycemic Diabetic Ketoacidosis in Concurrent Very Low-carbohydrate Diet and Sodium-glucose Transporter-2 Inhibitor Use: A Case Report [PDF]
, 2020 Introduction: With the incredibly high incidence of Type 2 Diabetes in the current population of emergency department patients, it is critical for clinicians to understand the possible complications of the treatment of this disease.
Ault, Brian +2 more
core
Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes [PDF]
, 2019 INTRODUCTION: Adequate persistence to antidiabetic treatment is highly important to achieve proper glycemic control. In this study we evaluate the persistence to treatment with dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors,
A McGovern +27 more
core +1 more source
Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection [PDF]
International Journal of Molecular Sciences, 2021 Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been approved as a new class of anti-diabetic drugs for type 2 diabetes mellitus (T2DM). The SGLT2 inhibitors reduce glucose reabsorption through renal systems, thus improving glycemic control in all stages of diabetes mellitus, independent of insulin.
Victor Chien-Chia Wu +2 more
openaire +2 more sources
Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. [PDF]
, 2016 Glucagon is one of the main regulators of blood glucose levels and dysfunctional stimulus secretion coupling in pancreatic A-cells is believed to be an important factor during development of diabetes.
Ahlstedt, I. +3 more
core +1 more source
Comparative risk of genital infections associated with sodium‐glucose co‐transporter‐2 inhibitors
Diabetes, obesity and metabolism, 2018 The extent to which sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors increase the risk of genital infections in routine clinical care, compared with other antidiabetic medications, is not clear, or whether the increased risk is consistent across gender
Chintan V. Dave +2 more
semanticscholar +1 more source
British medical journal, 2020 Objective To assess the association between use of sodium-glucose co-transporter 2 (SGLT2) inhibitors and risk of serious renal events in data from routine clinical practice.
B. Pasternak +10 more
semanticscholar +1 more source
The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: A bench to bedside review [PDF]
, 2014 INTRODUCTION: The treatment of type 2 diabetes mellitus (T2DM) continues to pose challenges for clinicians and patients. The dramatic rise in T2DM prevalence, which has paralleled the rise in obesity, has strained the healthcare system and prompted the ...
McGill, Janet B
core +2 more sources
Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
Российский кардиологический журнал, 2021 The article analyzes the new results of randomized clinical trials on the use of sodium-glucose co-transporter-2 inhibitors in patients with cardiovascular diseases, heart failure with and without type 2 diabetes.
E. V. Kovalenko +3 more
doaj +1 more source
Inhibitor binding mode and allosteric regulation of Na+-glucose symporters. [PDF]
, 2018 Sodium-dependent glucose transporters (SGLTs) exploit sodium gradients to transport sugars across the plasma membrane. Due to their role in renal sugar reabsorption, SGLTs are targets for the treatment of type 2 diabetes.
Althoff, Thorsten +9 more
core +2 more sources